Kymera Therapeutics appoints John Maraganore, Ph.D. to Board of Directors

Kymera Therapeutics, Inc.

John Maraganore, Ph.D. appointed to Kymera's Board effective January 17, 2022.
Dr. Maraganore will serve as a Class III director with term expiring at 2023 annual meeting.
Board determined Maraganore is independent under Nasdaq listing standards; committee compositions unchanged.
As non-employee director, he will receive cash and equity per Company's Non-Employee Director Compensation Policy.
No transactions requiring disclosure per Item 404(a) and no arrangements with others for selection.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John Maraganore

Director

KYMR · Kymera Therapeutics, Inc.

Effective: 2022-01-17
Filed: January 18, 2022, 6:59 PM ET

the Board appointed John Maraganore, Ph.D. to join the Board, effective as of January 17, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Maraganore was appointed as Director at Kymera Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed John Maraganore, Ph.D. to join the Board, effective as of January 17, 2022.

View on SEC.gov

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-011228

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.